ERBB2 and breast cancer: The results of the phase 3, multicenter, randomized DESTINY‐Breast05 study (ClinicalTrials.gov identifier: NCT04622319) investigating trastuzumab deruxtecan versus T‐DM1 as adjuvant therapy in patients with HER2‐positive early breast cancer will hopefully shed some light on this issue.